STOCK TITAN

Enlivex Therapeutics Ltd. - $ENLV STOCK NEWS

Welcome to our dedicated page for Enlivex Therapeutics Ltd. news (Ticker: $ENLV), a resource for investors and traders seeking the latest updates and insights on Enlivex Therapeutics Ltd. stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Enlivex Therapeutics Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Enlivex Therapeutics Ltd.'s position in the market.

Rhea-AI Summary

Enlivex Therapeutics (Nasdaq: ENLV) announced a $15 million registered direct offering with a healthcare-focused institutional investor.

The deal includes $5 million upfront for 3,571,429 ordinary shares at $1.40 per share and associated clinical milestone-linked warrants. The Series A warrants expire 18 months after issuance or 60 days post-publication of positive topline results from the ENX-CL-05-001 trial for Allocetra in knee osteoarthritis. Series B warrants expire 5.5 years after issuance or 60 days post-FDA filing for Allocetra's osteoarthritis indication.

Gross proceeds could total $10 million if all warrants are exercised. The offering closes around May 29, 2024, with H.C. Wainwright & Co. as the placement agent.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
-
Rhea-AI Summary

Enlivex Therapeutics (Nasdaq: ENLV) CEO, Oren Hershkovitz, updates shareholders on the progress of AllocetraTM, a macrophage reprogramming immunotherapy drug. The company released positive top-line data from a Phase II trial in patients with sepsis and demonstrated the potential effectiveness of AllocetraTM in high-risk urinary tract infection patients, along with a favorable safety profile. Enlivex sees a significant market opportunity in sepsis and osteoarthritis, believing each segment could represent a multi-billion dollar commercial chance. The company also began a Phase I/II trial for knee osteoarthritis patients. Enlivex is optimistic about the future impact of AllocetraTM and the potential to revolutionize medical treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.28%
Tags
none
-
Rhea-AI Summary
Enlivex announces dosing of first two patients in its randomized, controlled Phase I/II trial evaluating Allocetra™ in patients with knee osteoarthritis. The trial aims to assess the safety and efficacy of Allocetra™ injections in up to 160 patients with moderate to severe knee osteoarthritis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.79%
Tags
Rhea-AI Summary
Enlivex receives authorization from the Danish Regulatory Agency for Phase I/II Trial on Allocetra in Knee Osteoarthritis Patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.54%
Tags
-
Rhea-AI Summary
Enlivex Therapeutics announced a conference call to discuss topline results from its Phase II trial of Allocetra™ in sepsis patients. The trial included 120 patients, with the leadership team presenting and a live Q&A session.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-54.02%
Tags
conferences clinical trial
-
Rhea-AI Summary
Enlivex Therapeutics (ENLV) announces positive results from Phase II study of Allocetra™ in sepsis patients, showing significant reductions in SOFA scores and mortality rates. The study indicates a potential market opportunity for Allocetra™ in high-risk sepsis patients originating from urinary tract infections.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-54.02%
Tags
Rhea-AI Summary
Enlivex Therapeutics and Unusual Machines Inc. will be featured on the RedChip Small Stocks, Big Money™ show on Bloomberg TV. Enlivex Therapeutics, led by CEO Oren Hershkovitz, offers a promising investment opportunity in the biopharmaceutical sector with its innovative Allocetra™ cell therapy platform. The technology aims to reset immune cells for treating inflammatory and autoimmune diseases. On the other hand, Unusual Machines, under CEO Allan Evans, is focusing on the drone industry, acquiring valuable IP and brands to cater to various sectors. The company's subsidiaries, Fat Shark and Rotor Riot, are leading in FPV products and services, positioning Unusual Machines for long-term growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.51%
Tags
none
-
Rhea-AI Summary
Enlivex Therapeutics Ltd. (ENLV) launches a new trial for AllocetraTM, a cell therapy to treat osteoarthritis in the knee. The therapy aims to reprogram macrophages and rebalance the immune microenvironment. The trial, authorized by the Israeli Ministry of Health, will evaluate efficacy, safety, and tolerability in up to 160 patients. This innovative approach could provide a new option for patients suffering from knee osteoarthritis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
-
Rhea-AI Summary
Enlivex Therapeutics Ltd. (ENLV) is developing AllocetraTM, a cell therapy for sepsis treatment. The phase 2 trial of AllocetraTM has enrolled all 120 patients and is expected to release data by Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
Rhea-AI Summary
Enlivex Therapeutics Ltd. (ENLV) has received a new patent, US 11,883,429, from the U.S. Patent and Trademark Office for its immunotherapy product candidate, AllocetraTM. The patent provides additional intellectual property protection for the product's composition and manufacturing method in the United States.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.1%
Tags
none
Enlivex Therapeutics Ltd.

Nasdaq:ENLV

ENLV Rankings

ENLV Stock Data

25.96M
14.51M
11.81%
8.93%
1.27%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
14 Einstein St

About ENLV

enlivex therapeutics ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. its product candidate is allocetra, an immunotherapy candidate, which is in phase iib clinical trial in patients with severe sepsis; that is in investigator-initiated phase ii clinical trial for the treatment of covid-19 patients in severe and critical conditions; and which is in phase iia clinical trial for the prevention of graft versus host disease in allogeneic hematopoietic stem cell transplants (hsct) patients. the company is also developing allocetra for the prevention of complications associated with bone marrow transplantations and/or hsct, and acute multiple organ failure. it also intends to develop its cell-based therapy to be combined with treatments of solid tumors via immune checkpoint rebalancing to enhance the efficacy of various anti-cancer therapies, including chimeric antigen receptor t-cell therapy and therapies targeting t-cell re